Cytogen, Inc. (KOSDAQ:217330)
South Korea · Delayed Price · Currency is KRW
5,480.00
-230.00 (-4.03%)
At close: Feb 27, 2026
Revenue by Segment
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
| FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|
| Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
|---|
Liquid Biopsy Application Business | 5.12B | 866.06M | 615.15M | 347.85M |
Liquid Biopsy Application Business Growth | 491.23% | 40.79% | 76.85% | - |
Genome Technology Development and Analysis Services | 3.59B | - | - | - |
Toxicity and Molecular Diagnostic Tests | 2.20B | 2.32B | 145.63M | - |
Toxicity and Molecular Diagnostic Tests Growth | -5.26% | 1491.94% | - | - |
| 10.91B | 3.18B | 760.78M | 347.85M |
| 242.63% | 318.57% | 118.71% | - |
Revenue by Geography
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
| FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|
| Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
|---|
| 8.71B | 833.37M | 565.65M | 347.85M |
| 945.68% | 47.33% | 62.62% | - |
| 2.20B | 2.32B | 157.74M | - |
| -5.26% | 1369.68% | - | - |
| - | 32.69M | 37.39M | - |
| - | -12.55% | - | - |
| 10.91B | 3.18B | 760.78M | 347.85M |
| 242.63% | 318.57% | 118.71% | - |
Source: S&P Global Market Intelligence.
